海南海药股份有限公司 简式权益变动报告书 上市公司名称：海南海药股份有限公司 股票上市地点：深圳证券交易所 股票简称：海南海药 信息披露义务人：云南国际信托有限公司（代表"云南国际信托有限公司－聚利 36 号单一资金信托"） 住所： 云南省昆明市南屏街(云南国托大厦) 通讯地址：云南省昆明市南屏街 4 号信托大厦 A 座 33 楼 股份变动性质：股份减少。 签署日期：二零二六年二月二日 1 信息披露义务人声明 一、信息披露义务人依据《公司法》《证券法》《上市公司收购管理办法》《公开 发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》等相关法律、 法规编写本报告书。 二、依据上述法律法规的规定，本报告书已全面披露了信息披露义务人对海南海药 持有权益的股份变动情况。截至本报告书签署之日，除本报告书披露的持股信息外，信 息披露义务人没有通过其他方式增加或减少其在海南海药中拥有权益的股份。 股票代码：000566 三、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反信息 披露义务人章程或内部规则中的任何条款，或与之相冲突。 四、信息披露义务人承诺本报告书不存在虚假记载、误导性陈述或重 ...

关于副总经理退休辞职的公告 证券代码：000566 证券简称：海南海药 公告编号：2026-006 海南海药股份有限公司 本公司董事会及全体董事保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 海南海药股份有限公司（以下简称"公司"）董事会于近日收到公司副总经 理张晖女士的辞职报告，其因到龄退休申请辞去公司副总经理职务。辞职后，张 晖女士将不再担任海南海药股份有限公司任何职务，其辞职报告自送达公司董事 会之日起生效。 截至本公告日，张晖女士现持有公司股份 365,372 股；张晖女士辞职后，其 持有的公司股份将继续按照《上市公司董事和高级管理人员所持本公司股份及其 变动管理规则》《深圳证券交易所上市公司自律监管指引第 18 号——股东及董事、 高级管理人员减持股份》等相关规定进行管理。 二〇二六年二月四日 张晖女士在职期间恪尽职守、勤勉敬业，公司及董事会对张晖女士在任职期 间为公司所作的贡献表示衷心感谢。 特此公告 海南海药股份有限公司 董 事 会 ...

证券代码：000566 证券简称：海南海药 公告编号：2026-007 关于股东权益变动比例触及 1%及 5%整数倍暨 披露简式权益变动报告书的提示性公告 公司持股 5%以上股东云南国际信托有限公司－聚利 36 号单一资金信托保证 向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 一、权益变动基本情况 公司于 2026 年 1 月 10 日披露了《关于持股 5%以上股东减持股份的预披露 公告（公告编号：2026-004），公司股东聚利 36 号计划自该公告披露之日起 15 个交易日后的连续 90 个自然日内以集中竞价交易方式减持本公司股份不超过 12,973,651 股，占本公司总股本的 1%。 海南海药股份有限公司 重要内容提示: 1、 本次权益变动主要系云南国际信托有限公司－聚利 36 号单一资金信托 （以下简称"聚利 36 号"）在预披露的减持计划范围内减持股份。 2、本次权益变动后，聚利 36 号持有海南海药股份有限公司（以下简称"本 公司"或"公司"）股份 64,868,212 股，占公司总股本的 4. ...

Core Insights - The Chinese duty-free industry is experiencing a turning point due to improved policies, rising consumer confidence, and reduced external competition pressures, marking the establishment of a bottoming out phase for the industry [1][10]. Group 1: Industry Trends - The decline in the duty-free sector post-2020 was influenced by multiple factors, including increased competition from high commission models in Japan and South Korea, reduced consumer spending due to fluctuating income expectations, and limited supply from existing duty-free stores [1]. - Since 2023, government policies aimed at stimulating consumption have been effective, leading to a gradual recovery in consumer sentiment, particularly among middle to high-income households [3]. - The expansion of China's visa-free travel and cultural influence is enhancing the attractiveness of "China Travel" among international tourists, contributing to the recovery of passenger flow in port and city duty-free shops [6]. Group 2: Market Expansion - The duty-free market is set for rapid expansion with the introduction of 41 new port duty-free stores, as announced by the Ministry of Finance and other departments, aimed at increasing market scale through reasonable competition [6][10]. - The core duty-free market in Hainan is benefiting from favorable policies, with significant increases in sales figures, such as a 34.86% year-on-year growth in shopping amounts during the first week of new regulations [8]. Group 3: Company Insights - China Duty Free Group (601888) holds over 85% market share in Hainan's duty-free market, benefiting from zero tariffs and low corporate tax rates, with projected revenue growth from 45 billion to 60-65 billion yuan by 2026 [12]. - Hainan Airlines (600515) controls over 90% of air passenger flow in Hainan, with an increase in international routes expected to drive growth in air passenger and cargo transport [13]. - Hainan Haoyao (000566), while not a traditional duty-free operator, benefits from favorable policies in the biopharmaceutical sector, with a projected peak revenue contribution of 15 billion yuan from innovative drugs by 2026 [13].

Core Viewpoint - A number of listed companies are raising alarms about delisting risks as they release their 2025 performance forecasts, with several *ST companies already indicating they may not meet financial standards necessary to remain listed [1][2]. Group 1: Financial Performance and Delisting Risks - Several *ST companies, including *ST Guandian, *ST Yanshi, *ST Jinglun, and *ST Chuntian, have issued warnings about delisting risks due to poor financial performance [1]. - *ST Yanshi and *ST Jinglun have explicitly reached financial delisting indicators, with both companies expected to report revenues below 300 million yuan and losses in 2025 [2]. - *ST Yanshi forecasts revenues between 48 million to 60 million yuan and net losses between 180 million to 250 million yuan, indicating a significant deterioration in operational conditions [2][3]. Group 2: Audit Opinions and Compliance Issues - Companies like *ST Chun Tian and *ST Mu Bang are facing dual delisting risks due to both financial indicators and non-standard audit opinions, with auditors unable to confirm if their adjusted revenues will exceed 300 million yuan [4]. - *ST Jinglun's revenue is projected at 86.22 million yuan, which is below the 300 million yuan threshold, and the company is also facing scrutiny due to reliance on a single client for its new business [3]. - Non-standard audit opinions often indicate issues such as financial misreporting or severe doubts about a company's ability to continue as a going concern, which can trigger delisting [3][6]. Group 3: Regulatory Environment and Market Reactions - The tightening of delisting regulations has increased pressure on underperforming companies, with the revenue threshold for main board loss-making companies raised from 10 million to 30 million yuan [2]. - Regulatory authorities maintain a strict stance against "shell company" behaviors, as evidenced by the investigation into *ST Changyao for financial data misrepresentation, which could lead to severe penalties and delisting [8]. - The market is witnessing a trend of orderly and timely exits for underperforming companies, reflecting a shift towards a more stringent delisting mechanism [1][2].

海南海药1月30日公告，预计2025年度营业收入8亿元-9亿元，上年同期营业收入为9.91亿元。预计2025 年度归母净利润亏损3.5亿元-4.3亿元，上年同期亏损15.25亿元。 海南海药1月30日公告，预计2025年度营业收入8亿元-9亿元，上年同期营业收入为9.91亿元。预计2025 年度归母净利润亏损3.5亿元-4.3亿元，上年同期亏损15.25亿元。 ...

Core Viewpoint - Hainan Haiyao expects a net loss of 350 million to 430 million yuan in 2025 due to intensified market competition and various policy impacts [1] Group 1: Financial Outlook - The company anticipates a net loss ranging from 350 million to 430 million yuan for the year 2025 [1] - Increased depreciation expenses are expected as raw material projects transition to fixed assets [1] - High interest expenses are anticipated due to a large scale of interest-bearing liabilities, which will further impact the company's performance [1] Group 2: Market and Policy Environment - The competitive landscape is expected to intensify due to the influence of medical insurance and centralized procurement policies [1] - The company's innovative drugs have not yet been launched, and newly listed generic drugs have not gained significant market volume [1]

海南海药公告，预计2025年度净利润为负值。报告期内，公司归属于上市公司股东的净利润预计为亏损 3.5亿元至4.3亿元，亏损额较上年同期有所下降。 ...

证券代码：000566 证券简称：海南海药 公告编号：2026-005 海南海药股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要提示： 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 单位：万元 | 项 目 | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | -43,000 | ～ | -35,000 | -152,520.09 | | 扣除非经常性损益后的净利润 | -48,000 | ～ | -38,000 | -119,465.54 | | 基本每股收益（元/股） | -0.3314 | ～ | -0.2698 | -1.1756 | | 营业收入（如适用） | 80,000 | ～ | 90,000 | 99,070.15 | | 扣除后营业收入（如适用） | 78,000 | ～ | 88,000 | 96,267.22 | 二 ...

证券日报网讯1月27日，海南海药（000566）在互动平台回答投资者提问时表示，截至2026年1月20日公 司股东户数为132189户。 ...